Esophageal cancer: Neoadjuvant and adjuvant therapy

Shuang Qin Zhang, Victoria M. Villaflor*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter


The incidence of esophageal cancer has increased more than 15 % in the past 20 years. It ranks fifth in mortality rate among cancers. Squamous cell carcinoma (SCC) and adenocarcinoma (AC) account for the majority of all esophageal cancers. In developed countries, the incidence of AC of the esophagus has increased dramatically over the past couple of decades, whereas the incidence of SCC has decreased. Distinction on how the different histology should dictate treatment approach is not clear. For now, there is little evidence to support different treatment regimens for these two carcinomas. Based on calculations from a pool of cancer registries, the survival rate for patients with esophageal cancer is 33 % at 1 year and 10 % at 5 years. Survival rate of patients with local resectable disease after curative resection at 3 years was 20 %.

Original languageEnglish (US)
Title of host publicationEsophageal Diseases
Subtitle of host publicationEvaluation and Treatment
PublisherSpringer International Publishing
Number of pages14
ISBN (Electronic)9783319043371
ISBN (Print)9783319043364
StatePublished - Jan 1 2014


  • Adjuvant therapy
  • Chemotherapy
  • Esophageal cancer
  • Neoadjuvant therapy
  • Radiotherapy

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Esophageal cancer: Neoadjuvant and adjuvant therapy'. Together they form a unique fingerprint.

Cite this